Stem definition | Drug id | CAS RN |
---|---|---|
histamine-H1 receptor antagonists, tricyclic compounds | 814 | 100643-71-8 |
Dose | Unit | Route |
---|---|---|
5 | mg | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 0.00 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 5 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.23 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Date | Agency | Company | Orphan |
---|---|---|---|
Dec. 21, 2001 | FDA | MERCK SHARP DOHME |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Angioedema | 155.88 | 12.39 | 111 | 14820 | 37565 | 50552628 |
Urticaria | 109.23 | 12.39 | 161 | 14770 | 129400 | 50460793 |
Drug reaction with eosinophilia and systemic symptoms | 58.79 | 12.39 | 56 | 14875 | 28368 | 50561825 |
Allergy test positive | 52.82 | 12.39 | 14 | 14917 | 391 | 50589802 |
Erythema | 50.17 | 12.39 | 124 | 14807 | 146290 | 50443903 |
Hyponatraemia | 48.34 | 12.39 | 95 | 14836 | 96044 | 50494149 |
Toxic skin eruption | 43.86 | 12.39 | 32 | 14899 | 11219 | 50578974 |
Pruritus | 43.44 | 12.39 | 182 | 14749 | 283386 | 50306807 |
Hallucination, auditory | 42.93 | 12.39 | 31 | 14900 | 10697 | 50579496 |
Dermatitis bullous | 41.35 | 12.39 | 26 | 14905 | 7147 | 50583046 |
Haemangioma congenital | 37.99 | 12.39 | 11 | 14920 | 428 | 50589765 |
Death | 37.54 | 12.39 | 25 | 14906 | 325354 | 50264839 |
Terminal dribbling | 36.53 | 12.39 | 6 | 14925 | 11 | 50590182 |
Eczema | 34.69 | 12.39 | 38 | 14893 | 22664 | 50567529 |
Paranoia | 32.76 | 12.39 | 26 | 14905 | 10322 | 50579871 |
Rheumatoid arthritis | 31.97 | 12.39 | 10 | 14921 | 202540 | 50387653 |
Drug intolerance | 30.88 | 12.39 | 13 | 14918 | 219091 | 50371102 |
Victim of chemical submission | 29.17 | 12.39 | 8 | 14923 | 255 | 50589938 |
Blood immunoglobulin E increased | 28.72 | 12.39 | 14 | 14917 | 2345 | 50587848 |
Completed suicide | 28.27 | 12.39 | 3 | 14928 | 131886 | 50458307 |
Intentional overdose | 28.11 | 12.39 | 59 | 14872 | 62445 | 50527748 |
Cerebral thrombosis | 27.54 | 12.39 | 12 | 14919 | 1556 | 50588637 |
Face oedema | 27.50 | 12.39 | 30 | 14901 | 17809 | 50572384 |
Intentional self-injury | 27.47 | 12.39 | 34 | 14897 | 23078 | 50567115 |
Nasal ulcer | 26.72 | 12.39 | 12 | 14919 | 1671 | 50588522 |
Systemic lupus erythematosus | 25.96 | 12.39 | 5 | 14926 | 140617 | 50449576 |
Tooth injury | 25.82 | 12.39 | 10 | 14921 | 961 | 50589232 |
Skin dystrophy | 25.26 | 12.39 | 5 | 14926 | 35 | 50590158 |
Type IV hypersensitivity reaction | 25.13 | 12.39 | 13 | 14918 | 2469 | 50587724 |
Aggression | 24.99 | 12.39 | 31 | 14900 | 21085 | 50569108 |
Oxalosis | 24.56 | 12.39 | 5 | 14926 | 41 | 50590152 |
Gestational hypertension | 23.80 | 12.39 | 12 | 14919 | 2161 | 50588032 |
Somnolence | 23.29 | 12.39 | 99 | 14832 | 154886 | 50435307 |
Urticaria thermal | 22.59 | 12.39 | 6 | 14925 | 169 | 50590024 |
Drug ineffective | 22.43 | 12.39 | 146 | 14785 | 819187 | 49771006 |
Burn oral cavity | 22.40 | 12.39 | 5 | 14926 | 66 | 50590127 |
Hyperkalaemia | 22.33 | 12.39 | 46 | 14885 | 48043 | 50542150 |
Endocrine ophthalmopathy | 22.18 | 12.39 | 7 | 14924 | 366 | 50589827 |
Joint swelling | 21.96 | 12.39 | 24 | 14907 | 245262 | 50344931 |
Wound | 21.21 | 12.39 | 3 | 14928 | 105791 | 50484402 |
Tongue oedema | 19.86 | 12.39 | 13 | 14918 | 3826 | 50586367 |
Synovitis | 19.74 | 12.39 | 6 | 14925 | 123859 | 50466334 |
Dermatitis exfoliative generalised | 19.72 | 12.39 | 12 | 14919 | 3114 | 50587079 |
Hyperoxaluria | 19.32 | 12.39 | 5 | 14926 | 127 | 50590066 |
Therapeutic product effect decreased | 19.27 | 12.39 | 8 | 14923 | 136042 | 50454151 |
Hepatocellular injury | 18.65 | 12.39 | 30 | 14901 | 25917 | 50564276 |
Inflammatory bowel disease | 18.63 | 12.39 | 12 | 14919 | 3438 | 50586755 |
Acute kidney injury | 18.59 | 12.39 | 123 | 14808 | 227935 | 50362258 |
Guttate psoriasis | 18.21 | 12.39 | 6 | 14925 | 360 | 50589833 |
Treatment failure | 18.08 | 12.39 | 9 | 14922 | 137628 | 50452565 |
Nightmare | 18.06 | 12.39 | 23 | 14908 | 16063 | 50574130 |
HLA-B*27 positive | 17.28 | 12.39 | 5 | 14926 | 194 | 50589999 |
Rash erythematous | 16.96 | 12.39 | 34 | 14897 | 34818 | 50555375 |
Eosinophilia | 16.86 | 12.39 | 24 | 14907 | 18628 | 50571565 |
Keratopathy | 16.77 | 12.39 | 6 | 14925 | 462 | 50589731 |
Rash maculo-papular | 16.73 | 12.39 | 29 | 14902 | 26612 | 50563581 |
Urine oxalate increased | 16.42 | 12.39 | 5 | 14926 | 232 | 50589961 |
Pain | 16.38 | 12.39 | 102 | 14829 | 578801 | 50011392 |
Arteriospasm coronary | 16.34 | 12.39 | 11 | 14920 | 3391 | 50586802 |
Upper respiratory tract infection bacterial | 16.18 | 12.39 | 4 | 14927 | 84 | 50590109 |
Asthma | 15.75 | 12.39 | 60 | 14871 | 89277 | 50500916 |
Arrhythmia | 15.74 | 12.39 | 32 | 14899 | 33100 | 50557093 |
Abortion | 15.61 | 12.39 | 9 | 14922 | 2115 | 50588078 |
Photosensitivity reaction | 15.35 | 12.39 | 19 | 14912 | 12892 | 50577301 |
Patent ductus arteriosus | 15.19 | 12.39 | 11 | 14920 | 3809 | 50586384 |
Subretinal haematoma | 15.15 | 12.39 | 3 | 14928 | 21 | 50590172 |
Nasal pruritus | 14.96 | 12.39 | 5 | 14926 | 314 | 50589879 |
Amnestic disorder | 14.96 | 12.39 | 5 | 14926 | 314 | 50589879 |
Hypersensitivity pneumonitis | 14.87 | 12.39 | 9 | 14922 | 2313 | 50587880 |
Lip oedema | 14.57 | 12.39 | 10 | 14921 | 3183 | 50587010 |
Intraocular haematoma | 14.49 | 12.39 | 3 | 14928 | 27 | 50590166 |
Food intolerance | 14.44 | 12.39 | 9 | 14922 | 2435 | 50587758 |
Feeling hot | 14.24 | 12.39 | 34 | 14897 | 39168 | 50551025 |
Anaphylactic shock | 14.07 | 12.39 | 23 | 14908 | 20132 | 50570061 |
Psychotic disorder | 14.04 | 12.39 | 24 | 14907 | 21788 | 50568405 |
Contraindicated product administered | 13.96 | 12.39 | 14 | 14917 | 148944 | 50441249 |
Vitamin D deficiency | 13.91 | 12.39 | 17 | 14914 | 11385 | 50578808 |
Onycholysis | 13.57 | 12.39 | 7 | 14924 | 1321 | 50588872 |
Pharyngeal oedema | 13.49 | 12.39 | 18 | 14913 | 13147 | 50577046 |
White blood cell count decreased | 13.38 | 12.39 | 9 | 14922 | 116713 | 50473480 |
Fixed eruption | 13.38 | 12.39 | 6 | 14925 | 833 | 50589360 |
Systolic hypertension | 13.36 | 12.39 | 5 | 14926 | 437 | 50589756 |
Hepatic cytolysis | 13.14 | 12.39 | 14 | 14917 | 8089 | 50582104 |
Drug dose titration not performed | 13.13 | 12.39 | 5 | 14926 | 459 | 50589734 |
Pancoast's syndrome | 13.08 | 12.39 | 3 | 14928 | 45 | 50590148 |
Product use in unapproved indication | 13.00 | 12.39 | 68 | 14863 | 115751 | 50474442 |
Eyelid erosion | 12.96 | 12.39 | 3 | 14928 | 47 | 50590146 |
Toxic shock syndrome | 12.84 | 12.39 | 5 | 14926 | 487 | 50589706 |
Vertigo | 12.82 | 12.39 | 39 | 14892 | 51793 | 50538400 |
Swelling | 12.73 | 12.39 | 25 | 14906 | 200847 | 50389346 |
Urticaria chronic | 12.68 | 12.39 | 5 | 14926 | 504 | 50589689 |
Hernia hiatus repair | 12.68 | 12.39 | 3 | 14928 | 52 | 50590141 |
Hepatic lesion | 12.53 | 12.39 | 10 | 14921 | 3998 | 50586195 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Eosinophilia | 58.12 | 14.10 | 47 | 7532 | 22114 | 29544834 |
Toxic skin eruption | 52.14 | 14.10 | 32 | 7547 | 9725 | 29557223 |
Rash maculo-papular | 50.34 | 14.10 | 45 | 7534 | 24244 | 29542704 |
Dermatitis bullous | 46.66 | 14.10 | 25 | 7554 | 5881 | 29561067 |
Death | 41.49 | 14.10 | 18 | 7561 | 342066 | 29224882 |
Hepatic haematoma | 40.68 | 14.10 | 11 | 7568 | 384 | 29566564 |
Xerosis | 38.33 | 14.10 | 11 | 7568 | 479 | 29566469 |
Hyperkaliuria | 37.67 | 14.10 | 8 | 7571 | 96 | 29566852 |
Intentional overdose | 36.30 | 14.10 | 47 | 7532 | 38481 | 29528467 |
Eczema | 35.55 | 14.10 | 29 | 7550 | 13797 | 29553151 |
Corneal abscess | 35.06 | 14.10 | 6 | 7573 | 19 | 29566929 |
Urticaria | 32.98 | 14.10 | 54 | 7525 | 54606 | 29512342 |
Electrocardiogram QT prolonged | 32.36 | 14.10 | 43 | 7536 | 36094 | 29530854 |
Pruritus | 30.73 | 14.10 | 82 | 7497 | 116767 | 29450181 |
Rash pustular | 29.25 | 14.10 | 17 | 7562 | 4674 | 29562274 |
Miosis | 27.61 | 14.10 | 20 | 7559 | 7989 | 29558959 |
Purpura | 25.08 | 14.10 | 20 | 7559 | 9212 | 29557736 |
Blood immunoglobulin E decreased | 25.05 | 14.10 | 5 | 7574 | 43 | 29566905 |
Keratitis | 25.04 | 14.10 | 10 | 7569 | 1202 | 29565746 |
Angioedema | 24.11 | 14.10 | 35 | 7544 | 31880 | 29535068 |
Acute generalised exanthematous pustulosis | 24.08 | 14.10 | 16 | 7563 | 5567 | 29561381 |
Cholangiocarcinoma | 23.74 | 14.10 | 9 | 7570 | 941 | 29566007 |
Prurigo | 23.57 | 14.10 | 8 | 7571 | 608 | 29566340 |
Oedema genital | 23.21 | 14.10 | 7 | 7572 | 363 | 29566585 |
Arrhythmia | 23.16 | 14.10 | 34 | 7545 | 31279 | 29535669 |
Oral dysaesthesia | 22.15 | 14.10 | 5 | 7574 | 81 | 29566867 |
Bulbar palsy | 21.57 | 14.10 | 6 | 7573 | 233 | 29566715 |
Eyelid ptosis congenital | 21.55 | 14.10 | 5 | 7574 | 92 | 29566856 |
Type III immune complex mediated reaction | 21.21 | 14.10 | 6 | 7573 | 248 | 29566700 |
Myoglobin blood increased | 20.25 | 14.10 | 10 | 7569 | 1985 | 29564963 |
Dermatitis exfoliative | 19.80 | 14.10 | 15 | 7564 | 6410 | 29560538 |
Pemphigoid | 19.69 | 14.10 | 16 | 7563 | 7565 | 29559383 |
Dermatitis psoriasiform | 18.79 | 14.10 | 8 | 7571 | 1130 | 29565818 |
Hepatic cytolysis | 18.35 | 14.10 | 16 | 7563 | 8331 | 29558617 |
Retinopathy | 18.23 | 14.10 | 9 | 7570 | 1786 | 29565162 |
Spermatic cord disorder | 17.65 | 14.10 | 3 | 7576 | 9 | 29566939 |
Rhinitis allergic | 17.48 | 14.10 | 10 | 7569 | 2670 | 29564278 |
Hyperlipasaemia | 17.36 | 14.10 | 6 | 7573 | 481 | 29566467 |
Rhabdomyolysis | 17.31 | 14.10 | 44 | 7535 | 60764 | 29506184 |
Hypertrophic cardiomyopathy | 17.28 | 14.10 | 7 | 7572 | 872 | 29566076 |
Wrong product administered | 17.20 | 14.10 | 12 | 7567 | 4519 | 29562429 |
Purulent pericarditis | 16.98 | 14.10 | 3 | 7576 | 12 | 29566936 |
Rash erythematous | 16.80 | 14.10 | 24 | 7555 | 21538 | 29545410 |
Vasoplegia syndrome | 16.63 | 14.10 | 8 | 7571 | 1500 | 29565448 |
Intentional self-injury | 16.34 | 14.10 | 18 | 7561 | 12443 | 29554505 |
Wrong patient received product | 16.19 | 14.10 | 9 | 7570 | 2273 | 29564675 |
Coma | 16.18 | 14.10 | 33 | 7546 | 39417 | 29527531 |
Asthma | 15.93 | 14.10 | 30 | 7549 | 33819 | 29533129 |
Disease prodromal stage | 15.84 | 14.10 | 3 | 7576 | 19 | 29566929 |
Cerebral venous thrombosis | 15.78 | 14.10 | 6 | 7573 | 632 | 29566316 |
Pemphigus | 15.37 | 14.10 | 7 | 7572 | 1161 | 29565787 |
Neonatal pneumonia | 15.04 | 14.10 | 4 | 7575 | 131 | 29566817 |
Vascular cognitive impairment | 14.53 | 14.10 | 3 | 7576 | 31 | 29566917 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Angioedema | 137.39 | 11.93 | 127 | 19010 | 61694 | 64417901 |
Urticaria | 131.99 | 11.93 | 189 | 18948 | 147128 | 64332467 |
Toxic skin eruption | 82.13 | 11.93 | 58 | 19079 | 19226 | 64460369 |
Dermatitis bullous | 80.28 | 11.93 | 48 | 19089 | 12006 | 64467589 |
Pruritus | 72.21 | 11.93 | 230 | 18907 | 312170 | 64167425 |
Eosinophilia | 69.06 | 11.93 | 70 | 19067 | 38006 | 64441589 |
Eczema | 67.81 | 11.93 | 62 | 19075 | 29658 | 64449937 |
Death | 66.66 | 11.93 | 30 | 19107 | 482675 | 63996920 |
Rash maculo-papular | 58.56 | 11.93 | 71 | 19066 | 46955 | 64432640 |
Allergy test positive | 56.43 | 11.93 | 15 | 19122 | 421 | 64479174 |
Hallucination, auditory | 43.93 | 11.93 | 38 | 19099 | 16901 | 64462694 |
Erythema | 43.37 | 11.93 | 138 | 18999 | 186932 | 64292663 |
Drug reaction with eosinophilia and systemic symptoms | 43.32 | 11.93 | 66 | 19071 | 54151 | 64425444 |
Completed suicide | 39.66 | 11.93 | 9 | 19128 | 224405 | 64255190 |
Arrhythmia | 37.52 | 11.93 | 61 | 19076 | 52883 | 64426712 |
Terminal dribbling | 36.49 | 11.93 | 6 | 19131 | 11 | 64479584 |
Hyponatraemia | 35.81 | 11.93 | 111 | 19026 | 148228 | 64331367 |
Rash erythematous | 35.78 | 11.93 | 57 | 19080 | 48576 | 64431019 |
Electrocardiogram QT prolonged | 35.45 | 11.93 | 75 | 19062 | 79373 | 64400222 |
Face oedema | 35.16 | 11.93 | 40 | 19097 | 24721 | 64454874 |
Somnolence | 32.50 | 11.93 | 133 | 19004 | 203512 | 64276083 |
Aggression | 32.40 | 11.93 | 53 | 19084 | 46179 | 64433416 |
Hyperkaliuria | 32.35 | 11.93 | 8 | 19129 | 167 | 64479428 |
Hepatic cytolysis | 31.44 | 11.93 | 29 | 19108 | 14020 | 64465575 |
Hepatic haematoma | 31.07 | 11.93 | 11 | 19126 | 817 | 64478778 |
Intentional overdose | 30.29 | 11.93 | 76 | 19061 | 89868 | 64389727 |
Blood immunoglobulin E increased | 30.08 | 11.93 | 17 | 19120 | 3827 | 64475768 |
Corneal abscess | 28.65 | 11.93 | 6 | 19131 | 57 | 64479538 |
Drug intolerance | 28.65 | 11.93 | 10 | 19127 | 187982 | 64291613 |
Victim of chemical submission | 28.08 | 11.93 | 8 | 19129 | 292 | 64479303 |
Nasal ulcer | 27.78 | 11.93 | 12 | 19125 | 1514 | 64478081 |
Gestational hypertension | 26.67 | 11.93 | 12 | 19125 | 1669 | 64477926 |
Cerebral thrombosis | 26.65 | 11.93 | 13 | 19124 | 2169 | 64477426 |
Nightmare | 26.62 | 11.93 | 32 | 19105 | 20961 | 64458634 |
Rheumatoid arthritis | 26.33 | 11.93 | 8 | 19129 | 164286 | 64315309 |
Acute generalised exanthematous pustulosis | 25.76 | 11.93 | 26 | 19111 | 14032 | 64465563 |
Xerosis | 25.70 | 11.93 | 10 | 19127 | 967 | 64478628 |
Oedema genital | 24.64 | 11.93 | 8 | 19129 | 456 | 64479139 |
Paranoia | 24.21 | 11.93 | 27 | 19110 | 16325 | 64463270 |
Hepatocellular injury | 24.11 | 11.93 | 46 | 19091 | 45189 | 64434406 |
Skin dystrophy | 23.92 | 11.93 | 5 | 19132 | 47 | 64479548 |
Type IV hypersensitivity reaction | 23.75 | 11.93 | 14 | 19123 | 3408 | 64476187 |
Prurigo | 23.58 | 11.93 | 10 | 19127 | 1207 | 64478388 |
Burn oral cavity | 22.81 | 11.93 | 5 | 19132 | 60 | 64479535 |
Tooth injury | 22.49 | 11.93 | 10 | 19127 | 1353 | 64478242 |
Urticaria thermal | 22.38 | 11.93 | 6 | 19131 | 174 | 64479421 |
Vertigo | 22.14 | 11.93 | 52 | 19085 | 58959 | 64420636 |
Endocrine ophthalmopathy | 21.34 | 11.93 | 7 | 19130 | 412 | 64479183 |
Hyperkalaemia | 21.07 | 11.93 | 72 | 19065 | 101057 | 64378538 |
HLA-B*27 positive | 20.97 | 11.93 | 5 | 19132 | 89 | 64479506 |
Oxalosis | 20.33 | 11.93 | 5 | 19132 | 102 | 64479493 |
Abortion | 20.17 | 11.93 | 9 | 19128 | 1227 | 64478368 |
Bulbar palsy | 20.16 | 11.93 | 6 | 19131 | 256 | 64479339 |
Miosis | 19.80 | 11.93 | 22 | 19115 | 13244 | 64466351 |
Purpura | 19.79 | 11.93 | 25 | 19112 | 17221 | 64462374 |
Platelet count decreased | 19.35 | 11.93 | 13 | 19124 | 167698 | 64311897 |
Type III immune complex mediated reaction | 19.16 | 11.93 | 7 | 19130 | 569 | 64479026 |
Asthma | 19.15 | 11.93 | 67 | 19070 | 95158 | 64384437 |
Tongue oedema | 18.78 | 11.93 | 15 | 19122 | 5975 | 64473620 |
Rhinitis allergic | 18.71 | 11.93 | 17 | 19120 | 8061 | 64471534 |
Serum amyloid A protein increased | 18.65 | 11.93 | 5 | 19132 | 145 | 64479450 |
White blood cell count decreased | 18.52 | 11.93 | 12 | 19125 | 157825 | 64321770 |
Cholestasis | 18.45 | 11.93 | 41 | 19096 | 44831 | 64434764 |
Inflammatory bowel disease | 17.83 | 11.93 | 13 | 19124 | 4525 | 64475070 |
Guttate psoriasis | 17.64 | 11.93 | 6 | 19131 | 395 | 64479200 |
Sepsis | 17.26 | 11.93 | 26 | 19111 | 230315 | 64249280 |
Rhabdomyolysis | 17.13 | 11.93 | 63 | 19074 | 91663 | 64387932 |
Cerebral venous thrombosis | 16.98 | 11.93 | 10 | 19127 | 2431 | 64477164 |
Dermatitis exfoliative | 16.91 | 11.93 | 18 | 19119 | 10334 | 64469261 |
Dermatitis exfoliative generalised | 16.83 | 11.93 | 14 | 19123 | 5902 | 64473693 |
Keratitis | 16.78 | 11.93 | 11 | 19126 | 3226 | 64476369 |
Acute kidney injury | 16.67 | 11.93 | 205 | 18932 | 449035 | 64030560 |
Urine oxalate increased | 16.54 | 11.93 | 5 | 19132 | 225 | 64479370 |
Pancreatitis acute | 16.33 | 11.93 | 38 | 19099 | 42817 | 64436778 |
Cholangiocarcinoma | 15.99 | 11.93 | 9 | 19128 | 2009 | 64477586 |
Myoglobin blood increased | 15.89 | 11.93 | 10 | 19127 | 2737 | 64476858 |
Rash pustular | 15.81 | 11.93 | 17 | 19120 | 9868 | 64469727 |
Feeling hot | 15.80 | 11.93 | 39 | 19098 | 45624 | 64433971 |
Photosensitivity reaction | 15.76 | 11.93 | 23 | 19114 | 18150 | 64461445 |
Hyperoxaluria | 15.73 | 11.93 | 5 | 19132 | 266 | 64479329 |
Arteriospasm coronary | 15.69 | 11.93 | 13 | 19124 | 5452 | 64474143 |
Hyperlipasaemia | 15.36 | 11.93 | 7 | 19130 | 1003 | 64478592 |
Hypersensitivity vasculitis | 15.21 | 11.93 | 14 | 19123 | 6747 | 64472848 |
Anaphylactic shock | 15.13 | 11.93 | 30 | 19107 | 30298 | 64449297 |
Upper respiratory tract infection bacterial | 15.06 | 11.93 | 4 | 19133 | 112 | 64479483 |
Disease progression | 15.02 | 11.93 | 12 | 19125 | 141668 | 64337927 |
Onycholysis | 14.95 | 11.93 | 8 | 19129 | 1618 | 64477977 |
Therapeutic product effect incomplete | 14.92 | 11.93 | 6 | 19131 | 103476 | 64376119 |
Lip oedema | 14.18 | 11.93 | 12 | 19125 | 5177 | 64474418 |
Retinopathy | 14.04 | 11.93 | 10 | 19127 | 3355 | 64476240 |
Vascular cognitive impairment | 13.93 | 11.93 | 3 | 19134 | 33 | 64479562 |
Synovitis | 13.88 | 11.93 | 6 | 19131 | 99084 | 64380511 |
Altered state of consciousness | 13.78 | 11.93 | 33 | 19104 | 37869 | 64441726 |
Drug level increased | 13.78 | 11.93 | 31 | 19106 | 34165 | 64445430 |
Keratopathy | 13.76 | 11.93 | 6 | 19131 | 774 | 64478821 |
Oral dysaesthesia | 13.71 | 11.93 | 4 | 19133 | 159 | 64479436 |
Pemphigoid | 13.61 | 11.93 | 18 | 19119 | 12968 | 64466627 |
Coronavirus infection | 13.52 | 11.93 | 12 | 19125 | 5518 | 64474077 |
Urticaria chronic | 13.24 | 11.93 | 5 | 19132 | 446 | 64479149 |
Therapeutic product effect decreased | 13.22 | 11.93 | 9 | 19128 | 115342 | 64364253 |
Dermatitis psoriasiform | 12.89 | 11.93 | 8 | 19129 | 2138 | 64477457 |
Cryopyrin associated periodic syndrome | 12.77 | 11.93 | 3 | 19134 | 50 | 64479545 |
Nutritional condition abnormal | 12.54 | 11.93 | 6 | 19131 | 960 | 64478635 |
Hyperthermia | 12.51 | 11.93 | 19 | 19118 | 15531 | 64464064 |
Febrile neutropenia | 12.37 | 11.93 | 23 | 19114 | 187634 | 64291961 |
Purulent pericarditis | 12.25 | 11.93 | 3 | 19134 | 60 | 64479535 |
Acute haemorrhagic oedema of infancy | 12.25 | 11.93 | 3 | 19134 | 60 | 64479535 |
Amnestic disorder | 12.20 | 11.93 | 5 | 19132 | 554 | 64479041 |
Hypersensitivity pneumonitis | 12.11 | 11.93 | 9 | 19128 | 3223 | 64476372 |
Eyelid erosion | 11.98 | 11.93 | 3 | 19134 | 66 | 64479529 |
Neutrophil count decreased | 11.93 | 11.93 | 4 | 19133 | 77192 | 64402403 |
None
Source | Code | Description |
---|---|---|
ATC | R06AX27 | RESPIRATORY SYSTEM ANTIHISTAMINES FOR SYSTEMIC USE ANTIHISTAMINES FOR SYSTEMIC USE Other antihistamines for systemic use |
FDA MoA | N0000000190 | Histamine H1 Receptor Antagonists |
FDA EPC | N0000175587 | Histamine-1 Receptor Antagonist |
MeSH PA | D018678 | Cholinergic Agents |
MeSH PA | D018680 | Cholinergic Antagonists |
MeSH PA | D018494 | Histamine Agents |
MeSH PA | D006633 | Histamine Antagonists |
MeSH PA | D006634 | Histamine H1 Antagonists |
MeSH PA | D039563 | Histamine H1 Antagonists, Non-Sedating |
MeSH PA | D018377 | Neurotransmitter Agents |
CHEBI has role | CHEBI:37955 | H1 receptor antagonists |
CHEBI has role | CHEBI:48873 | acetylcholine receptor antagonist |
CHEBI has role | CHEBI:49103 | drug metabolites |
CHEBI has role | CHEBI:50857 | anti-allergic drugs |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Vasomotor rhinitis | indication | 8229003 | DOID:4730 |
Allergic urticaria | indication | 40178009 | DOID:10612 |
Allergic rhinitis | indication | 61582004 | |
Nasal discharge | indication | 64531003 | |
Nasal congestion | indication | 68235000 | |
Sneezing | indication | 76067001 | |
Common cold | indication | 82272006 | DOID:10459 |
Chronic idiopathic urticaria | indication | 302162004 | |
Seasonal allergic rhinitis | indication | 367498001 | |
Allergic conjunctivitis | indication | 473460002 | DOID:11204 |
Hyperthyroidism | contraindication | 34486009 | DOID:7998 |
Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
Coronary arteriosclerosis | contraindication | 53741008 | DOID:3393 |
Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
Kidney disease | contraindication | 90708001 | DOID:557 |
Disease of liver | contraindication | 235856003 | DOID:409 |
Benign prostatic hyperplasia | contraindication | 266569009 | |
Retention of urine | contraindication | 267064002 | |
Angle-closure glaucoma | contraindication | 392291006 | DOID:13550 |
Hypertensive urgency | contraindication | 443482000 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 8.92 | Basic |
pKa2 | 2.48 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Histamine H1 receptor | GPCR | ANTAGONIST | Ki | 9.40 | WOMBAT-PK | CHEMBL | |||
Sodium-dependent serotonin transporter | Transporter | Ki | 6.91 | DRUG MATRIX | |||||
Sodium-dependent noradrenaline transporter | Transporter | Ki | 5.96 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 2A | GPCR | Ki | 8.03 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 2B | GPCR | Ki | 7.55 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 2C | GPCR | Ki | 7.80 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 6 | GPCR | Ki | 6.00 | DRUG MATRIX | |||||
Alpha-2B adrenergic receptor | GPCR | Ki | 6.01 | DRUG MATRIX | |||||
D(3) dopamine receptor | GPCR | Ki | 6.19 | DRUG MATRIX | |||||
Histamine H2 receptor | GPCR | Ki | 5.97 | DRUG MATRIX | |||||
Histamine H4 receptor | GPCR | IC50 | 4.80 | CHEMBL | |||||
Muscarinic acetylcholine receptor M1 | GPCR | Ki | 7.74 | WOMBAT-PK | |||||
Muscarinic acetylcholine receptor M2 | GPCR | Ki | 7.60 | WOMBAT-PK | |||||
Muscarinic acetylcholine receptor M3 | GPCR | Ki | 7.49 | WOMBAT-PK | |||||
Muscarinic acetylcholine receptor M4 | GPCR | Ki | 7.70 | WOMBAT-PK | |||||
Muscarinic acetylcholine receptor M5 | GPCR | Ki | 7.30 | WOMBAT-PK | |||||
Sodium-dependent dopamine transporter | Transporter | Ki | 5.51 | DRUG MATRIX | |||||
Multidrug resistance protein 1 | Transporter | IC50 | 4.37 | WOMBAT-PK | |||||
Alpha-1B adrenergic receptor | GPCR | Ki | 5.70 | DRUG MATRIX |
ID | Source |
---|---|
4021292 | VUID |
N0000148729 | NUI |
D03693 | KEGG_DRUG |
275635 | RXNORM |
4021292 | VANDF |
C0908935 | UMLSCUI |
CHEBI:291342 | CHEBI |
CHEMBL1172 | ChEMBL_ID |
DB00967 | DRUGBANK_ID |
C121345 | MESH_SUPPLEMENTAL_RECORD_UI |
124087 | PUBCHEM_CID |
7157 | IUPHAR_LIGAND_ID |
7817 | INN_ID |
FVF865388R | UNII |
16243 | MMSL |
42606 | MMSL |
51632 | MMSL |
83662 | MMSL |
d04785 | MMSL |
009081 | NDDF |
134506008 | SNOMEDCT_US |
396015008 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Clarinex | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-815 | TABLET, FILM COATED | 5 mg | ORAL | NDA | 23 sections |
Desloratadine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42291-240 | TABLET | 5 mg | ORAL | ANDA | 26 sections |
Clarinex | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-0765 | TABLET, FILM COATED | 5 mg | ORAL | NDA | 29 sections |
Desloratadine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-3975 | TABLET | 5 mg | ORAL | ANDA | 30 sections |
DESLORATADINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-4794 | TABLET, FILM COATED | 5 mg | ORAL | ANDA | 27 sections |
Clarinex | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-4624 | TABLET, FILM COATED | 5 mg | ORAL | NDA | 12 sections |
Clarinex-D 12 Hour | HUMAN PRESCRIPTION DRUG LABEL | 2 | 54868-5708 | TABLET, EXTENDED RELEASE | 2.50 mg | ORAL | NDA | 29 sections |
Desloratadine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55111-360 | TABLET, ORALLY DISINTEGRATING | 5 mg | ORAL | ANDA | 26 sections |
Desloratadine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55111-551 | TABLET, ORALLY DISINTEGRATING | 2.50 mg | ORAL | ANDA | 26 sections |
Desloratadine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62250-619 | TABLET | 5 mg | ORAL | ANDA | 25 sections |
Desloratadine | Human Prescription Drug Label | 1 | 62756-523 | TABLET, FILM COATED | 5 mg | ORAL | ANDA | 28 sections |
DESLORATADINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68180-153 | TABLET, FILM COATED | 5 mg | ORAL | ANDA | 27 sections |
Desloratadine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69543-107 | TABLET | 5 mg | ORAL | ANDA | 29 sections |
DESLORATADINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71335-1000 | TABLET, FILM COATED | 5 mg | ORAL | ANDA | 27 sections |
Clarinex | HUMAN PRESCRIPTION DRUG LABEL | 1 | 78206-119 | TABLET, FILM COATED | 5 mg | ORAL | NDA | 30 sections |
Clarinex | HUMAN PRESCRIPTION DRUG LABEL | 1 | 78206-119 | TABLET, FILM COATED | 5 mg | ORAL | NDA | 30 sections |
CLARINEX-D 12 HOUR | HUMAN PRESCRIPTION DRUG LABEL | 2 | 78206-120 | TABLET, EXTENDED RELEASE | 2.50 mg | ORAL | NDA | 29 sections |
CLARINEX-D 12 HOUR | HUMAN PRESCRIPTION DRUG LABEL | 2 | 78206-120 | TABLET, EXTENDED RELEASE | 2.50 mg | ORAL | NDA | 29 sections |